Background Giant-cell arteritis (GCA) is an inflammatory disease of large/medium-sized arteries, frequently involving the temporal arteries (tA). Inflammation-induced vascular remodelling leads to vaso-occlusive events. Circulating endothelin-1 (Et-1) is increased in patients with GCA with ischaemic complications suggesting a role for Et-1 in vascular occlusion beyond its vasoactive function. Objective to investigate whether Et-1 induces a migratory myofibroblastic phenotype in human tAderived vascular smooth muscle cells (VSMC) leading to intimal hyperplasia and vascular occlusion in GCA.
InTROduCTIOn
Giant-cell arteritis (GCA) is a granulomatous vasculitis targeting large and medium-sized arteries in aged individuals. 1 2 Inflammation-induced vascular remodelling results in intimal hyperplasia leading to symptoms of vascular insufficiency or irreversible ischaemic complications in 20%-30% of patients. [3] [4] [5] [6] It is generally assumed that vascular smooth muscle cells (VSMC) migrate through disrupted elastic fibres towards the intima where they produce abundant matrix proteins. 6 However, underlying mechanisms remain virtually unexplored. Several growth factors, including PDGF, TGFβ, EGF, NGF or BDNF, are expressed in GCA lesions and may participate in this process based on their ability to stimulate proliferation and/or migration of VSMC in vitro. 7 8 Visual loss, the most frequent ischaemic complication in GCA, is frequently preceded by transient episodes of blindness (amaurosis fugax) suggesting that reversible vasospasm may initially contribute to flow reduction in small arteries supplying the optic nerve. [3] [4] [5] Endothelin-1 (ET-1) is a potent vasoactive peptide that might potentially participate in this process. 9 10 ET-1 is mainly synthesised by endothelial cells although VSMC and macrophages may also produce it. 9 11 ET-1 signals through two G-protein coupled receptors (GPCR): E-1 receptors A and B (ET A R and ET B R). Both ET A R and ET B R mediate VSMC contraction. Signalling through ET B R on endothelial cells may also produce vasodilatation by stimulating nitric oxide and prostacyclin production. 9 10 12 Although the majority of previous studies on ET-1 functions have focused on VSMC regulation of the vascular tone, in recent years, skin, liver and lung fibroblasts have been identified as important targets of ET-1. 13 14 ET-1 promotes myofibroblast differentiation of fibroblasts, a crucial step in the development of fibrogenic diseases such as systemic sclerosis and cardiac, pulmonary or hepatic fibrosis. [13] [14] [15] The inflammatory milieu of GCA is enriched in cytokines and growth factors able to enhance ET-1 expression such as TGFβ among others. 9 16 We and others have recently shown that ET-1, ET A R and ET B R are increased in GCA lesions, although the specific cells expressing the ET-1 system components have not been determined. 17 18 In spite of the short half-life of circulating ET-1, plasma ET-1 concentrations are elevated in patients with GCA-related cranial ischaemic complications. 18 Since arteries involved by GCA are usually larger than resistance arteries controlling vascular tone, we hypothesised that, in addition to its vasoactive function, ET-1 might contribute to the development of intimal hyperplasia by stimulating a myofibroblast 
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phenotype in VSMC and promoting their migration towards the intimal layer. Consequently, we investigated the effect of ET-1 on human temporal artery (TA)-derived VSMC migration in vitro and ex vivo as well as the signalling pathways involved.
MeThOdS

Patient samples
TA biopsies were performed to 10 patients with suspected GCA (see online supplementary table S1). Five biopsies disclosed typical GCA histopathological features and were used in the indicated experiments. The remaining five showed no inflammatory lesions and served as controls. Patients with negative biopsies were eventually diagnosed with other conditions (see online supplementary table S2). The study was approved by the local Ethics Committee (Hospital Clinic of Barcelona) and patients signed informed consent.
Isolation and culture of VSMC derived from human TA
Human TA-derived VSMCs were obtained from explanted TA sections from the above patients cultured on Matrigel and characterised by flow cytometry, as described. 7 18 19 In specific experiments, VSMCs were cocultured with peripheral blood mononuclear cells (PBMC) or purified subsets (CD4+ T cells or CD14+ monocytes) (online supplementary methods).
Reagents
See online supplementary methods.
Immunofluorescence
Immunofluorescence staining was performed in cultured VSMC or in fresh-frozen or cultured TA sections. Antibodies used, dilutions and detailed steps are depicted in online supplementary methods.
Quantitative real-time reverse transcription PCR
RNA was extracted from cultured VSMC using TRIzol Reagent (Life Technologies, Paisley, UK). Prepro-ET-1 and α-smooth muscle actin (αSMA) mRNAs (1 µg) were measured by quantitative reverse transcription PCR with specific TaqMan gene expression assays from Applied Biosystems as reported. 18 
eT-1 immunoassay
ET-1 in cell supernatants was measured using R&D Quantikine ELISA Kit.
Migration assay
VSMC migration was assessed using Boyden chambers with 10 μm pore polyester filters. Further details are exposed in the online supplementary methods.
Scratch wound-healing assay
VSMCs were seeded at 80% confluence onto 0.1% gelatin-precoated 12-well plates and cultured overnight. One scratch per well was done before adding fresh Dulbecco's modified Eagle medium supplemented with 50 mmol/L of HEPES (Sigma-Aldrich) and BQ123, BQ788 (20 μmol/L) or combination of both inhibitors. ET-1 (10 −9 mol/L) or fresh medium was added to each corresponding well. Time-lapse video microscopy was applied to record cell movement and results were analysed as depicted in online supplementary methods. A proliferation assay was also performed to assess the potential impact of ET-1 on cell growth (see online supplementary figure S1).
Western blot and gelatin zymography
See details in online supplementary methods. 20 21 
Transient transfection
Focal adhesion kinase (FAK) wild-type cDNA and FAK point mutants Y397F and Y925F, cloned into the pCDNA3 expression vector, were kindly provided by Kazue Matsumoto and Kenneth M Yamada (National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland) and generated as previously described. 20 22 Lipofectamine 2000 Reagent (Invitrogen) was used for transient transfection of VSMC. Transfection efficiency was about 30% (see online supplementary figure S2).
ex vivo-cultured TA sections from patients with GCA TA sections from four treatment-naive patients with GCA and four controls were cultured on Matrigel as described, 19 23 with or without BQ123 or BQ788 (20 μmol/L). VSMC outgrowth was scored in three arteries at various time points by two investigators (EPR and MCB) blinded to the conditions tested. 
Statistical analysis
Mann-Whitney U test for independent variables was applied using SPSS software, PASW V.22.0.
ReSulTS distribution of the eT-1 system in GCA lesions compared with controls
In control arteries, slight ET-1 expression was observed in organised VSMC in the media and in the luminal endothelium ( figure 1A) . In GCA-involved arteries, ET-1 was intensively expressed by clusters of infiltrating inflammatory cells (figure 1B, b.1 and figure 1C , c.1) and by scattered remaining VSMC (figure 1B, b.2). In addition, ET-1 expression by the luminal endothelium was increased (figure 1B,C) compared with control arteries ( figure 1A) .
To further characterise the cell types responsible for ET-1 production in GCA, primary cultures of VSMC were obtained from normal TA and cocultured with purified CD4+ T lymphocytes or monocytes (CD14+) from healthy donors in order to mimic vascular inflammation. 24 Interestingly, a slight but consistent increase in prepro-ET-1 mRNA expression was observed in CD4+ T lymphocytes and to a lesser extent in CD14+ monocytes, when cocultured with VSMC ( figure 1D ). VSMC remarkably expressed and secreted mature ET-1 ( figure 1E ). When in coculture, unprocessed big ET-1 increased in PBMC and decreased in VSMC lysates. Overall, secreted ET-1, mainly produced by VSMC, decreased in coculture supernatants ( figure 1F ). The increase in prepro-ET-1 mRNA in PBMC cocultured with VSMC was confirmed in three paired experiments performed with PBMC and VSMC from the same GCA donor ( figure 1G) .
Expression of ET A R and ET B R was explored in the same TA specimens. In control arteries, ET A R was expressed by VSMC in the media whereas ET B R was hardly detected ( figure 1H,I ). In GCA, both ET A R and ET B R receptors were expressed by αSMA-positive cells at the intima-media border (figure 1J,K). Endothelial cells and inflammatory cells also expressed both ET receptors (figure 1J,K).
eT-1 promotes VSMC cytoskeleton reorganisation and migration through eT A R and eT B R
To investigate whether ET-1 promoted a myofibroblast phenotype in VSMC, we explored changes in cytoskeleton organisation induced by ET-1 in cultured TA-derived VSMC. ET-1 elicited 
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spreading of VSMC with a striking formation of cytoplasm protrusions (figure 2A). Cell spreading was not induced in VSMC cultured on polylysine and was more remarkable when VSMCs were cultured on fibronectin (figure 2A), suggesting participation of integrin-mediated signalling pathways in this process. 25 Spreading was reverted by blocking ET-1 signalling with ET A R antagonist BQ123 and ET B R antagonist BQ788 ( figure 2A) .
ET-1-induced VSMC morphology changes were associated with increased migratory activity (see online supplementary movie). ET-1 exposure resulted in significantly faster scratchwound closure (figure 2B). ET A R and ET B R antagonists (BQ123 and BQ788, respectively) and combination of both inhibitors significantly abrogated ET-1-induced VSMC migration, indicating implication of both receptors in this process (figure 2B). ET-1 did not accelerate scratch-wound closure by stimulating VSMC growth, since no significant increase in VSMC proliferation was elicited by ET-1 (online supplementary figure S1 ).
ET-1 induced VSMC migration in Boyden chambers when added to the upper compartment (figure 2C). In contrast, when ET-1 was added to the lower compartment, no differences in migration were observed, indicating that ET-1 has no chemoattractant activity and primarily stimulates motility (figure 2C). ET-1-induced migration was abrogated by BQ788 and BQ123 or the combination of both (figure 2D). 
FAK phosphorylation at Y397 is essential for eT-1 induction of VSMC migration
Based on the relevance of integrin engagement in ET-1-induced cytoskeleton reorganisation, and the seminal role of FAK in integrin-mediated cell motility, we explored the involvement of FAK in ET-induced VSMC migration. FAK is a docking and signalling tyrosine kinase with a seminal role in focal adhesion turnover required for cell migration in response to integrin binding or growth factor signalling. [25] [26] [27] FAK activation results in autophosphorylation of crucial tyrosine residues. [25] [26] [27] One of the best characterised is Y397 which provides a binding site for Src-type tyrosine kinases promoting their recruitment to focal adhesions and allowing their phosphorylation. This interaction is essential for cell migration in fibroblasts and malignant cells. [26] [27] [28] [29] Src, in turn, phosphorylates additional tyrosine residues, including Y925, located within the focal adhesion targeting sequence at the FAK C-terminal domain. 30 Phosphorylated Y925 may recruit the adaptor protein Grb2, leading to activation of the GTP-binding protein Ras, and to ERK1/2 activation. 30 ET-1 increased phosphorylation of Y397 and Y925 FAK residues (figure 3A), particularly when cells were cultured on plastic or fibronectin whereas this effect was absent in cells plated on polylysine ( figure 3A,B) . FAK phosphorylation was reduced by ET A R or ET B R antagonists BQ123 and BQ788 ( figure 3A) . As G-coupled receptors, ET-1 receptors may activate heterotrimeric G proteins which have important roles in integrin inside-out and outside-in signalling. 31 Pertussis toxin induces ADP-ribosylation of several Gα i subunits inhibiting their activity. 32 As shown in figure 3C , ET-1-induced Y397 FAK phosphorylation was abrogated by pertussis toxin confirming the participation of heterotrimeric G proteins in ET-1-induced FAK activation.
To confirm the role of FAK in ET-1-induced VSMC migration, we investigated the effect of PF-573228, an inhibitor of FAK kinase activity. At concentrations able to inhibit FAK phosphorylation (see online supplementary figure S3), PF-573228 significantly decreased ET-1-induced VSMC cytoskeleton organisation and migration in a dose-dependent manner ( figure 3D,E) . Interestingly, at low concentrations, PF-573228 inhibited ET-1-induced migration whereas at higher concentrations it was also able to reduce baseline VSMC migration.
Consistent with a seminal role of FAK in mediating ET-1-induced migration, transient transfection of VSMC with FAK wild type significantly increased VSMC migration through Boyden chambers overcoming the effect of ET-1 which was not able to increase migration in FAK-overexpressing cells. However, transient transfection with an expression vector containing FAK Y397F point mutation abrogated ET-1-induced motility. In spite that ET-1 also increased Y925 phosphorylation, transfection of Y925F point mutant had no impact on ET-1-induced migration ( figure 3F ). These results indicate the crucial participation of FAK Y397 in ET-1-mediated migration in primary TA-derived VSMC.
It has been previously reported that integrin engagement and FAK signalling trigger rapid secretion of gelatinases MMP9 and MMP2 by lymphoid cells. 20 33 Based on the important role of ET-1 in inducing FAK activation, we explored whether ET-1 modulated secretion of gelatinases by VSMC. ET-1 slightly increased secretion of pro-MMP2 (figure 3G) and this effect was reduced by BQ788 (ET B R antagonist) ( figure 3H ).
ET-1 induced FAK phosphorylation and recruitment of phosphorylated FAK at the focal adhesions in the leading and rear edges and colocalisation with αSMA ( figure 4A,B) .
To confirm the relevance of the above results in GCA, cultured TA sections from patients with GCA were assessed for FAK phosphorylation. As shown in figure 4C ,D, Y397-phosphorylated FAK was detected in GCA lesions, particularly at the intima and intima/media junction and FAK phosphorylation decreased upon exposure to ET A R and ET B R antagonists.
Src and PI3kinases mediate eT-1-induced VSMC migration
Considering the relevance of FAK Y397 in ET-1-induced VSMC migration, we next explored FAK downstream pathways involved in cell migration including ERK, Src and PI3K. [26] [27] [28] [29] [30] ET-1 promoted Src activation revealed by increased phosphorylation of the Y416 Src residue and this was inhibited by both ET A R and ET B R antagonists (figure 5A).
ERK1/2 activation has a crucial role in cell motility, by phosphorylating myosin light chains and as scaffolding molecule. 26 27 34 Although transfection with Y925F point mutant did not substantially reduce ET-1-induced migration, ET-1 increased ERK1/2 phosphorylation and this was reduced by ET-1 receptor antagonists (figure 5A), consistent with the existence of alternative ERK activating mechanisms dependent and independent of FAK. 26 30 Although the effect of ET-1 on baseline-activated Src and ERK phosphorylation was modest, it was consistently observed.
In accordance with the crucial role of Src in cell migration, Src inhibitor PP2 reduced baseline and ET-1-induced VSMC migration. Interestingly, PI3kinase inhibition with LY294002 selectively reduced ET-1-increased migration (figure 5B). ERK inhibition of ET-1-induced migration could not be assessed with PD98059 due to the decreased viability observed after the 6-hour exposure required for migration experiments (see online supplementary figure S4 ). Short-term exposure to Src and ERK inhibitors, not reducing cell viability, virtually impeded cell spreading (figure 5C) whereas PI3kinase inhibition only reduced the increase in cell protrusions induced by ET-1 ( figure 5C,D) .
FAK Y397 interaction with p85, the regulatory subunit of PI3ki-nase, is crucial to cell migration in other experimental contexts. 35 36 ET-1 promoted colocalisation of PI3kinase p85 with FAK at VSMC focal adhesions ( figure 5D ). This interaction was abrogated by both ET A R and ET B R antagonists and by inhibition of FAK kinase activity. Inhibition of PI3kinase by LY294002 prevented formation of fully developed cell protrusions induced by ET-1, but did not prevent ET-1-induced recruitment of p85 and FAK at the focal contacts in nascent, immature buds ( figure 5D ).
eT-1 induces neointima formation in ex vivo-cultured normal TA
In control arteries, αSMA-expressing quiescent VSMCs were concentrically organised ( figure 6A ). In contrast, in GCA-involved arteries the muscular layer was disrupted and αSMA-expressing VSMCs were mostly located at the neointima ( figure 6A ). Treatment of cultured TA explants with ET-1 at concentrations similar to those found in patient plasma 18 or in the coculture supernatants increased αSMA expression ( figure 6B,C) . Exposure of cultured normal TA to ET-1 also resulted in a striking disruption of the muscular layer and migration of VSMC towards the intima (figure 6B). GCA ( figure 6D ). Blocking ET B R with BQ788 remarkably inhibited VSMC outgrowth from GCA-involved arteries ( figure 6E ). The effect of blocking ET A R with BQ123 was less intense but also delayed VSMC outgrowth ( figure 6E ). Taking together, these data support a seminal role of ET-1 in inducing neointima formation in GCA.
dISCuSSIOn
Expression of ET-1 was increased in GCA lesions compared with normal arteries. In GCA, infiltrating leukocytes accounted for the majority of ET-1 expression, which was also enhanced in the luminal endothelium. Some ET-1 expression was also observed in remaining VSMC. Coculture experiments supported that, in an 
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inflammatory microenvironment, ET-1 production is increased in mononuclear cells and decreases in VSMC. ET A R was constitutively expressed by VSMC in normal arteries but, in the context of vascular inflammation, both ET receptors were remarkably increased and expressed by endothelial cells, VSMC and infiltrating leukocytes. As previously reported, the increase in ET B R was much more prominent. 17 ET-1 stimulated VSMC migration through FAK activation, revealed by ET-1-enhanced FAK autophosphorylation at Y397, creating binding sites for Src kinase and the p85 regulatory subunit of PI3kinase, a crucial process in cell motility. 29 30 35 ET-1 promoted colocalisation of activated FAK and p85-PI3kinase at the focal adhesions. Subsequent signalling cascades participating in cell motility in other cell types, such as Src and ERK, were also slightly activated. Interestingly, while FAK and Src inhibitors strongly reduced both baseline and ET-1-induced migration, PI3kinase inhibitor selectively inhibited the increase in migration induced by ET-1. Class I PI3kinases are activated by tyrosine kinases whereas class II PI3kinases are activated through GPCR. 36 37 It is likely that ET-1 promotes activation of both classes of PI3kinases through FAK activation and through GPCR ET A R and ET B R. In addition, GPCR-induced heterotrimeric G-protein activation may It has been previously shown that FAK coordinates migration with matrix metalloproteinase (MMP) release, which is necessary for cell progression through the extracellular matrix. 20 ET-1 moderately stimulated release of MMP2 by VSMC, a process mostly mediated by ET B R in our experimental conditions. Since MMP2 has elastinolytic activity, ET-1-induced MMP-2 release may be relevant to the disruption of the internal elastic lamina, characteristically observed 
in GCA lesions, allowing VSMC migration from the muscular to the intimal layer. 6 21 38 FAK has received substantial attention in pathological processes where cell migration is seminal including cancer and fibrosis. 14 28 Our data suggest that FAK is involved in vascular remodelling. Supporting our findings, a recent study has evidenced Y397 phosphorylated FAK in the resistance arteries undergoing vascular remodelling in hypertension. 39 Selective myeloid deletion of FAK does not influence vascular remodelling in a mouse model, suggesting that expression and activation of FAK in VSMC rather than inflammatory cells may be relevant to vascular occlusion. 40 Moreover, a naturally occurring truncated form of FAK, FRNK, which acts as competitive inhibitor of FAK, inhibits VSMC invasion in a carotid rat injury model. 41 Consequently, our results indicate that ET-1-mediated activation of FAK in VSMC may have a seminal role in vascular remodelling in the context of vascular inflammation where ET-1 is mainly produced by inflammatory cells and their production is amplified through interactions with VSMC. These newly recognised functions of ET-1 on VSMC may have a broader impact and may operate in vascular diseases with prominent vascular remodelling beyond GCA. To date, in the field of vascular biology, attention has mainly focused on the vasoconstriction role of ET-1 and only responses related to vascular reactivity or hypertension have been explored after conditional deletion of ET A R in VSMC. 9 10 41 In a pioneer study performed in mice more than one decade ago, induced overexpression of ET-1 in endothelial cells resulted in increased vascular remodelling. 42 However, this interesting observation has not been further explored.
Based on its presumed major function, ET-1 has been considered a therapeutic target for vascular diseases where vasoconstriction is thought to play a major role such as systemic or pulmonary hypertension or, more recently, fibrotic diseases, such as scleroderma or lung fibrosis, according to the newly recognised functions of ET-1 on fibroblasts. 9 10 13 14 However, to date, clinical trials with ET-1 receptor antagonists have shown the best efficacy for diseases with prominent vascular remodelling such as ischaemic ulcers in systemic sclerosis or pulmonary hypertension rather than vasoconstriction or fibrotic diseases. 9 10 43 There is an unmet need of treatments reducing inflammation-induced vascular remodelling in GCA since patients with systemic vasculitis may develop complications derived from vascular occlusion in spite of glucocorticoid or immunosuppressive therapy. 44 Our data underline an unprecedented and crucial role for ET-1 in inducing vascular remodelling and vascular occlusion in the context of vascular inflammation and point towards endothelin receptor antagonists as potential therapeutic targets to avoid maladaptive vascular remodelling in inflammatory diseases of blood vessels.
